Price transparency and trade-margin control in essential medicines
Quick dive
- The Supreme Court was informed of a proposed 30% trade-margin cap for patented and non-patented cancer medicines.
- The Court questioned why price regulation should be limited to cancer medicines and asked the government to examine a wider cap for medicines and medical products.
- The Bench referred to disparities in which some cancer medicines had mark-ups approaching 1,000% and an India-made cardiac stent costing about ₹5,000 was reportedly sold for more than ₹25,000.
- The Court linked price control to availability and patient protection, while the government cautioned that a uniform cap across all medicines could have unintended consequences.
- exam_relevance: tests essential medicines, DPCO price control, National Pharmaceutical Pricing Authority, trade margins and Article 21 health concerns; it echoes UPSC Mains GS-II questions on healthcare and Prelims questions on drug regulation, using the 30%/16%/1,000% figures as testable distinctions.
Full explanation
This explanation is available with full current-affairs access.
Log in to continue